Loading...
Loading...
OCEA| Name | Value |
|---|---|
| Revenues | 0.0 |
| Cost of Revenue | 0.0 |
| Gross Profit | 0.0 |
| Operating Expense | -1,017,833.0 |
| Operating I/L | -1,017,833.0 |
| Other Income/Expense | 0.0 |
| Interest Income | 0.0 |
| Pretax | -1,017,833.0 |
| Income Tax Expense | 0.0 |
| Net Income/Loss | -1,017,833.0 |
Ocean Biomedical, Inc. is a biopharmaceutical company specializing in the discovery and development of therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company's revenue is generated through the development of mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for non-small cell lung cancer and glioblastoma multiforme, a small molecule product candidate targeting Chit1 for Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome, as well as product candidates based on the WPDS platform, including a malaria vaccine candidate, a humanized mAb malaria therapeutic candidate, and a small molecule malaria therapeutic candidate. Additionally, the company is developing a product candidate for the treatment of COVID-19 in hospitalized patients.
